- Home
- LGCY vs SKYE Comparison
LGCY vs SKYE Comparison
Compare LGCY & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGCY
- SKYE
- Stock Information
- Founded
- LGCY 2009
- SKYE 2012
- Country
- LGCY United States
- SKYE United States
- Employees
- LGCY N/A
- SKYE N/A
- Industry
- LGCY
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- LGCY
- SKYE Health Care
- Exchange
- LGCY NYSE
- SKYE Nasdaq
- Market Cap
- LGCY 87.3M
- SKYE 80.7M
- IPO Year
- LGCY 2024
- SKYE N/A
- Fundamental
- Price
- LGCY $6.45
- SKYE $1.44
- Analyst Decision
- LGCY Strong Buy
- SKYE Buy
- Analyst Count
- LGCY 2
- SKYE 6
- Target Price
- LGCY $10.65
- SKYE $16.60
- AVG Volume (30 Days)
- LGCY 33.0K
- SKYE 1.7M
- Earning Date
- LGCY 02-13-2025
- SKYE 05-09-2025
- Dividend Yield
- LGCY N/A
- SKYE N/A
- EPS Growth
- LGCY 44.62
- SKYE N/A
- EPS
- LGCY 0.58
- SKYE N/A
- Revenue
- LGCY $52,722,310.00
- SKYE N/A
- Revenue This Year
- LGCY $33.77
- SKYE N/A
- Revenue Next Year
- LGCY $19.89
- SKYE N/A
- P/E Ratio
- LGCY $11.12
- SKYE N/A
- Revenue Growth
- LGCY 32.68
- SKYE N/A
- 52 Week Low
- LGCY $3.60
- SKYE $1.14
- 52 Week High
- LGCY $10.37
- SKYE $17.65
- Technical
- Relative Strength Index (RSI)
- LGCY N/A
- SKYE 40.43
- Support Level
- LGCY N/A
- SKYE $1.26
- Resistance Level
- LGCY N/A
- SKYE $3.73
- Average True Range (ATR)
- LGCY 0.00
- SKYE 0.34
- MACD
- LGCY 0.00
- SKYE 0.04
- Stochastic Oscillator
- LGCY 0.00
- SKYE 11.40
About LGCY LEGACY EDUCATION INC
Legacy Education Inc is engaged in career-focused, post-secondary education services to students at all stages of adult life, from recent high school graduates to working parents.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.